Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma

Oncotarget

Volumn 6, Issue 41, 2015, Pages 44037-44048

  Luo, Xiao Lin ^a   Zhong, Guang Zheng ^b   Hu, Li Yang ^a   Chen, Jie ^b   Liang, Ying ^a   Chen, Qiu Yan ^a   Liu, Qing ^a   Rao, Hui Lan ^a   Chen, Kai Lin ^a   Cai, Qing Qing ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apolipoprotein A I (ApoA I); Non metastatic nasopharyngeal carcinoma (NPC); Prognosis

Indexed keywords

APOLIPOPROTEIN A1; APOA1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS FREE SURVIVAL; FEMALE; HUMAN; LOCAL RECURRENCE FREE SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NASOPHARYNX CARCINOMA; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL RATE; ADOLESCENT; AGED; AREA UNDER THE CURVE; BLOOD; CHILD; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MORTALITY; NASOPHARYNX TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN A-I; AREA UNDER CURVE; BIOMARKERS, TUMOR; CHILD; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84952949194     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5823     Document Type: Article

References (31)

1. Lee AW, Lin JC, Ng WT. Current management of nasopharyngeal cancer. Semin Radiat Oncol. 2012; 22:233-244.
2. Yoshizaki T, Ito M, Murono S, Wakisaka N, Kondo S, Endo K. Current understanding and management of nasopharyngeal carcinoma. Auris Nasus Larynx. 2012; 39:137-144.
3. Muir CS. Cancer Incidence in Five Continents. Classification. IARC Sci Publ. 1992; 25-30.
4. Lee AW, Lau WH, Tung SY, Chua DT, Chappell R, Xu L, Siu L, Sze WM, Leung TW, Sham JS, Ngan RK, Law SC, Yau TK, Au JS, O'Sullivan B, Pang ES, et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. J Clin Oncol. 2005; 23:6966-6975.
5. Van Hemelrijck M, Walldius G, Jungner I, Hammar N, Garmo H, Binda E, Hayday A, Lambe M, Holmberg L. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study. Cancer Causes Control. 2011; 22:1011-1019.
6. Wang L, Chi PD, Chen H, Xiang J, Xia ZJ, Zhang YJ. Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma. Tumour Biol. 2014; 35:2141-2149.
7. Hsieh Wu J. Lipoprotein(a) in vascular disease, cancer and longevity. Chang Gung Med J. 2011; 34:555-564.
8. Chi PD, Liu W, Chen H, Zhang JP, Lin Y, Zheng X, Dai S. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma. PLoS One. 2014; 9:e91080.
9. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348:1625-1638.
10. Gaziano JM, Hennekens CH. Dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1995; 87:1427-1428.
11. Michalaki V, Koutroulis G, Syrigos K, Piperi C, Kalofoutis A. Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem. 2005; 268:19-24.
12. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, Frohlich J, Ayyobi A, Overvad K, Toft-Petersen AP, Tjonneland A, Hansen L, Boutron-Ruault MC, Clavel-Chapelon F, Cottet V, Palli D, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut. 2011; 60:1094-1102.
13. Siemianowicz K, Gminski J, Stajszczyk M, Wojakowski W, Goss M, Machalski M, Telega A, Brulinski K, Magiera-Molendowska H. Serum total cholesterol and triglycerides levels in patients with lung cancer. Int J Mol Med. 2000; 5:201-205.
14. Tamura T, Inagawa S, Hisakura K, Enomoto T, Ohkohchi N. Evaluation of serum high-density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. J Gastroenterol Hepatol. 2012; 27:1635-1640.
15. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC Jr. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol. 2011; 122:548-553.
16. Han C, Zhang HT, Du L, Liu X, Jing J, Zhao X, Yang X, Tian B. Serum levels of leptin, insulin, and lipids in relation to breast cancer in china. Endocrine. 2005; 26:19-24.
17. Chang SJ, Hou MF, Tsai SM, Wu SH, Hou LA, Ma H, Shann TY, Tsai LY. The association between lipid profiles and breast cancer among Taiwanese women. Clin Chem Lab Med. 2007; 45:1219-1223.
18. Ehmann M, Felix K, Hartmann D, Schnolzer M, Nees M, Vorderwulbecke S, Bogumil R, Buchler MW, Friess H. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas. 2007; 34:205-214.
19. Jiang R, Yang ZH, Luo DH, Guo L, Sun R, Chen QY, Huang PY, Qiu F, Zou X, Cao KJ, Mai HQ, Guo X, Qian CN, Hong MH, Chen MY. Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma. Med Oncol. 2014; 31:80.
20. Cheng T, Dai X, Zhou DL, Lv Y, Miao LY. Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced nonsmall cell lung cancer. Med Oncol. 2015; 32:407.
21. Brewer HB Jr., Fairwell T, LaRue A, Ronan R, Houser A, Bronzert TJ. The amino acid sequence of human APOA-I, an apolipoprotein isolated from high density lipoproteins. Biochem Biophys Res Commun. 1978; 80:623-630.
22. Yui Y, Aoyama T, Morishita H, Takahashi M, Takatsu Y, Kawai C. Serum prostacyclin stabilizing factor is identical to apolipoprotein A-I (Apo A-I). A novel function of Apo A-I. J Clin Invest. 1988; 82:803-807.
23. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005; 365:2041-2054.
24. Eliopoulos AG, Stack M, Dawson CW, Kaye KM, Hodgkin L, Sihota S, Rowe M, Young LS. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors. Oncogene. 1997; 14:2899-2916.
25. Crowl RM, Stoller TJ, Conroy RR, Stoner CR. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem. 1991; 266:2647-2651.
26. Tietge UJ, Maugeais C, Cain W, Grass D, Glick JM, de Beer FC, Rader DJ. Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem. 2000; 275:10077-10084.
27. Tietge UJ, Maugeais C, Lund-Katz S, Grass D, deBeer FC, Rader DJ. Human secretory phospholipase A2 mediates decreased plasma levels of HDL cholesterol and apoA-I in response to inflammation in human apoA-I transgenic mice. Arterioscler Thromb Vasc Biol. 2002; 22:1213-1218.
28. Zamanian-Daryoush M, Lindner D, Tallant TC, Wang Z, Buffa J, Klipfell E, Parker Y, Hatala D, Parsons-Wingerter P, Rayman P, Yusufishaq MS, Fisher EA, Smith JD, Finke J, DiDonato JA, Hazen SL. The cardioprotective protein apolipoprotein A1 promotes potent antitumorigenic effects. J Biol Chem. 2013; 288:21237-21252.
29. Honn KV, Cicone B, Skoff A. Prostacyclin: a potent antimetastatic agent. Science. 1981; 212:1270-1272.
30. Xiang Y, Yao H, Wang S, Hong M, He J, Cao S, Min H, Song E, Guo X. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma. Laryngoscope. 2006; 116:126-130.
31. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012; 13:633-641.